https://www.selleckchem.com/Androgen-Receptor.html
043) as well as destination therapy and bridge-to-transplant (184 ± 88 m vs 102 ± 82 m, P = .005). Patients with VAD implantation had statistically and clinically significant improvements in EC and QoL as assessed with the MNH during CR. Patients on destination therapy showed a larger benefit from CR than bridge-to-transplant patients and patients with left VAD improved more than biventricular VAD patients. Patients with VAD implantation had statistically and clinically significant improvements in EC and QoL as assessed with the MNH du